Search

Your search keyword '"T, Miyamoto"' showing total 5,732 results
Start Over Author "T, Miyamoto"
5,732 results on '"T, Miyamoto"'

1. Terahertz-field-induced polar charge order in electronic-type dielectrics

Author

H. Yamakawa, T. Miyamoto, T. Morimoto, N. Takamura, S. Liang, H. Yoshimochi, T. Terashige, N. Kida, M. Suda, H. M. Yamamoto, H. Mori, K. Miyagawa, K. Kanoda, and H. Okamoto

Subjects
Science
Abstract

Photoinduced phase transition is a central issue in the field of non-equilibrium quantum physics. Here, the authors demonstrate that a terahertz electric-field pulse changes a Mott insulator of an organic molecular compound to a macroscopically polarized charge-order state.

Published
2021
Full Text
View/download PDF

2. Rapid diagnostic testing of a neonate in a family with hypertrophic cardiomyopathy

Author

H. Ueda, T. Miyamoto, Y. Tsurusaki, G. Minase, N. Matsumoto, and K. Sengoku

Subjects
early diagnosis, hypertrophic cardiomyopathy, mutation, myh7, whole-exome sequencing, Gynecology and obstetrics, RG1-991
Abstract

Familial hypertrophic cardiomyopathy (HCM) is a common but severe genetic disease. A pregnant woman with familial HCM was referred to our hospital as both the couple and their families were concerned that the baby would later develop HCM. Therefore, we determined the risk of HCM in the neonate. Using whole-exome sequencing, mutational analysis was performed on the patient, her family members (including her father, mother, sister, and husband), and the neonate. Sanger sequencing was also performed. We found that HCM in this family was caused by a mutation in the cardiac heavy chain β-myosin (MYH7) gene. Encouragingly, the neonate did not carry this MYH7 mutation as the father was also negative. We were able to determine that the neonate had no risk of familial HCM. Obstetricians should consider genetic screening if a pregnant woman has a severe risk of such familial complications. Content: We demonstrated absence of familial HCM in a neonate and suggest appropriate genetic screening in pregnant women with familial complications.

Published
2020
Full Text
View/download PDF

3. EFETIVIDADE, IMUNOGENICIDADE E SEGURANÇA DA MEIA DOSE DA VACINA CHADOX1 NCOV-19 CONTRA SARS-COV2 (PROJETO VIANA)

Author

Valéria Valim, Maria da Penha Gomes Gouvea, Olindo Assis Martins Filho, Andrea Teixeira Carvalho, Luiz Antônio Bastos Camacho, Daniel A. Maciel Villela, Lauro Ferreira Pinto Neto, Carla Domingues, Isac Ribeiro Moulaz, Beatriz Paoli Thompson, Karen Evelin Monlevade Lança, Gabriela Curto Cristianes Lacerda, João Pedro Gonçalvez Lenzi, Sabrina de Souza Ramos, João Pedro Moraes Miossi, Matheus Leite Rassele, Felipe de Castro Pimentel, Allan Gonçalves Henriques, Maria Eduarda Moraes Hibner Amaral, Lucas Santos Silva, Laís Pasti, Gabriel Smith Sobral Vieira, Thais Luma de Oliveira Roza, Alessandro Demoner Ramos, Heitor Filipe Surlo, Luiza Lorenzoni Grillo, Laura Gonçalves Rodrigues Aguiar, Matheus Pereira Rossi, Ramon Borge Rizzi, Paula dos Santos Athayde, Pietra Zava Lorencini, Adriana Santos Silva, Tania Reuter, Jaquelini Jubini, Danielle Grillo Pacheco Lyra, Rodrigo Ribeiro Rodrigues, Cristiano Soares da Silva, Luís Carlos Reblin, Orlei Cardoso, Samira T. Miyamoto, Ketty Lysie Libardi Lira Machado, Ludimila Forechi, Carolina Strauss, Jadher Percio, Lely Stella Guzmán Barrera, Nésio Fernandes de Medeiros Junior, and José Geraldo Mill

Subjects
Infectious and parasitic diseases, RC109-216, Microbiology, QR1-502
Abstract

Introdução: A escassez de insumos tem sido uma grande limitação para o avanço da vacinação. O objetivo deste estudo foi avaliar a efetividade, imunogenicidade e segurança da meia dose da ChAdOx1 nCoV-19. Métodos: Ensaio clínico controlado não randomizado de fase III com grupos de comparação interna e externa (profissionais de saúde vacinados com dose plena). Moradores de Viana-ES, 18-49 anos, receberam duas meias doses da ChAdOx1 nCoV-19, com intervalo de 8 semanas. Foram estudados a incidência novos casos, número de mortes, internações e admissões em UTI, anticorpos neutralizantes por teste de neutralização em placa (PRNT) e quimioluminescência contra a porção RBD da fração S1 da proteína Spike, anticorpos totais IgG específico para SARS-Cov2, fatores solúveis sistêmicos, imunidade celular por estimulação antígeno-específica de células mononucleares do sangue periférico in vitro e investigação de Linfócitos T e B de memória e de citocinas intracitoplasmáticas. Eventos adversos foram monitorizados por diário, registro em plataforma digital, busca ativa por telefone, notificações no E-SUS notifica. Tempos de coleta: antes, 28 dias após 1ª.(D1) e 2ª. (D2) doses, e seguimento 3,6,12 meses pós D2. Resultados: Dos 27.000 elegíveis, 20.546 indivíduos receberam duas meias doses. Desses, 572 coletaram amostras biológicas. Após D2, a taxa de soroconversão entre soronegativos no baseline (n = 239) foi 99,8% semelhante à dose plena (DP) (n = 104, 100%). A média geométrica dos títulos de anticorpos (IC95%; UA/dL) foi 1.324 (1.148-1.527) com a MD e 3.727 (2.975-4.668) com DP (p < 0,001). No subgrupo com infecção natural prévia, os títulos foram semelhantes à dose padrão, mas houve queda dos títulos após D2 comparado com D1 nos dois grupos (MD = 9.569 (8.768-10.443) vs. 5.742 (3.195-6.347)), (DP = 9.533 (7.377-12.319) vs. 4.915 (3.767-6.412)). A frequência de eventos adversos foi semelhante, mas a duração dos sintomas foi menor no grupo MD. Não ocorreram eventos adversos graves. Taxas de casos confirmados após imunização completa foi semelhante à dose plena (20/248.830 vs. 28/419.248 casos/pessoas dia). Conclusão: Meia dose da ChAdOx1 nCoV-19 é segura, imunogênica e capaz de induzir anticorpos neutralizantes em 99,8%. Em pessoas que tiveram infecção natural, uma meia dose foi semelhante a dose plena, e suficiente para induzir altos títulos de anticorpos. Resultados de imunidade celular e efetividade estão sendo analisados. Apoio: ICEPi/SESA, MS, PNI, OPAS, HUCAM, UFES, EBSERH.

Published
2022
Full Text
View/download PDF

4. REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)

Author

Maria da Penha Gomes Gouvea, Olindo Assis Martins Filho, Andrea Teixeira Carvalho, Luiz Antônio Bastos Camacho, Daniel A. Maciel Villela, Lauro Ferreira Pinto Neto, Carla Domingues, Isac Ribeiro Moulaz, Thayná Martins Gouveia, Beatriz Paoli Thompson, Karen Evelin Monlevade Lança, Gabriela Curto Cristianes Lacerda, João Pedro Gonçalves Lenzi, Sabrina de Souza Ramos, João Pedro Moraes Miossi, Matheus Leite Rassele, Felipe de Castro Pimentel, Thais Luma de Oliveira Roza, Alessandro Demoner Ramos, Allan Gonçalves Henriques, Maria Eduarda Moraes Hibner Amaral, Heitor Filipe Surlo, Gabriel Smith Sobral Vieira, Laís Pizzol Pasti, Luiza Lorenzoni Grillo, Laura Gonçalves Rodrigues Aguiar, Matheus Pereira Rossi, Ramon Borge Rizzi, Paula dos Santos Athayde, Pietra Zava Lorencini, Adriana Santos Silva, Tania Reuter, Jaquelini Jubini, Danielle Grillo Pacheco Lyra, Rodrigo Ribeiro Rodrigues, Cristiano Soares da Silva, Luís Carlos Reblin, Orlei Cardoso, Samira T. Miyamoto, Ketty Lysie Libardi Lira Machado, Ludimila Forechi, Carolina Strauss, Jadher Percio, Lely Stella Guzmán Barrera, Nésio Fernandes de Medeiros Junior, Karina Rosemarie Lallemand, Manoel Rodrigues Lima Neto, José Geraldo Mill, and Valéria Valim

Subjects
Infectious and parasitic diseases, RC109-216, Microbiology, QR1-502
Abstract

Introdução: A escassez de insumos tem limitado o avanço da vacinação contra a Covid-19, no mundo. A vacinação com meia dose da ChAdOx1 nCOv-19 foi comparada à dose padrão no Estudo Viana. O objetivo deste estudo foi avaliar e monitorar os eventos adversos com meia dose e comparar com dose padrão. Métodos: Ensaio clínico de fase III que testou meia dose da ChAdOx1 nCoV-19 (AZD1222) em adultos de 18 a 49 anos da cidade de Viana - Espírito Santo. Os eventos adversos foram avaliados por meio de registros no sistema e-SUS notifica, busca ativa e estudos de casos de eventos adversos pós-vacina (EAVP) e eventos adversos de interesse especial (EAIE), telefone celular e 0800 disponível aos participantes, questionário eletrônico 7 e 30 dias após a primeira e segunda dose, busca ativa SAC Fiocruz e disque intoxicações, busca ativa de rumores no CIEVS, vigilância de todos os óbitos do município. Em uma subamostra, os eventos adversos foram avaliados por diário auto-aplicável e entrevista aos participantes, 28 dias após a primeira (D1) e a segunda dose (D2). O mesmo questionário foi aplicado numa coorte de trabalhadores da saúde, ajustado por idade, que recebeu 2 doses de dose padrão. Resultados: Foram incluídos 20.546 participantes. Desses, 572 foram convidados a responder um diário de eventos adversos. Dessa subamostra, 501 e 381 devolveram os diários pós D1 e D2. Não houve reações graves. Os sintomas mais frequentes foram (84% e 52%, p

Published
2022
Full Text
View/download PDF

5. Ionic to neutral conversion induced by resonant excitation of molecular vibrations coupled to intermolecular charge transfer

Author

T. Morimoto, H. Suzuki, T. Otaki, N. Sono, N. Kida, T. Miyamoto, and H. Okamoto

Subjects
Physics, QC1-999
Abstract

In organic molecular compounds, intramolecular vibration is sometimes coupled with intermolecular charge transfer (CT). In such materials, vibrational excitation by a midinfrared (MIR) pulse causes collective intermolecular CTs that can be a route to an electronic-state conversion. Here, we report that an ionic-to-neutral (IN) conversion in tetrathiafulvalene-p-chloranil (TTF-CA) can be driven by a strong vibrational excitation induced by an MIR pulse. Using MIR-pump subcycle-reflectivity-probe and second-harmonic-generation-probe measurements, we discuss the coherent electron and lattice dynamics during and after the IN conversion, which are distinct from the dynamics of the photoinduced transition by electronic excitation alone.

Published
2021
Full Text
View/download PDF

6. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

Author

Alexandre R Zlotta, Leslie K Ballas, Andrzej Niemierko, Katherine Lajkosz, Cynthia Kuk, Gus Miranda, Michael Drumm, Andrea Mari, Ethan Thio, Neil E Fleshner, Girish S Kulkarni, Michael A S Jewett, Robert G Bristow, Charles Catton, Alejandro Berlin, Srikala S Sridhar, Anne Schuckman, Adam S Feldman, Matthew Wszolek, Douglas M Dahl, Richard J Lee, Philip J Saylor, M Dror Michaelson, David T Miyamoto, Anthony Zietman, William Shipley, Peter Chung, Siamak Daneshmand, and Jason A Efstathiou

Subjects
Oncology
Published
2023

7. Understanding Fatigue in Sjögren’s Syndrome: Outcome Measures, Biomarkers and Possible Interventions

Author

Elisabeth Mæland, Samira T. Miyamoto, Daniel Hammenfors, Valeria Valim, and Malin V. Jonsson

Subjects
Sjögren’s sydrome, fatigue, outcome measure, cytokines, biomarker (BM), intervention, Immunologic diseases. Allergy, RC581-607
Abstract

Sjögren’s syndrome (SS) is an autoimmune disease affecting the salivary and lacrimal glands. Symptoms range from dryness to severe extra-glandular disease involving manifestations in the skin, lungs, nervous system, and kidney. Fatigue occurs in 70% of patients, characterizing primary SS (pSS) and significantly impacting the patient’s quality of life. There are some generic and specific instruments used to measure fatigue in SS. The mechanisms involved with fatigue in SS are still poorly understood, but it appears fatigue signaling pathways are more associated with cell protection and defense than with pro-inflammatory pathways. There are no established pharmacological treatment options for fatigue in pSS. So far, exercise and neuromodulation techniques have shown positive effects on fatigue in pSS. This study briefly reviews fatigue in pSS, with special attention to outcome measures, biomarkers, and possible treatment options.

Published
2021
Full Text
View/download PDF

8. Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies

Author

Jacob Ukleja, Erika Kusaka, and David T. Miyamoto

Subjects
immunotherapy, radiation therapy, renal cancer, bladder cancer, prostate cancer, genitourinary cancer (GU cancer), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Immunotherapy drugs have recently been approved by the Food and Drug Administration for the treatment of several genitourinary malignancies, including bladder cancer, renal cancer, and prostate cancer. Preclinical data and early clinical trial results suggest that immune checkpoint inhibitors can act synergistically with radiation therapy to enhance tumor cell killing at local irradiated sites and in some cases at distant sites through an abscopal effect. Because radiation therapy is commonly used in the treatment of genitourinary malignancies, there is great interest in testing the combination of immunotherapy with radiation therapy in these cancers to further improve treatment efficacy. In this review, we discuss the current evidence and biological rationale for combining immunotherapy with radiation therapy, as well as emerging data from ongoing and planned clinical trials testing the efficacy and tolerability of this combination in the treatment of genitourinary malignancies. We also outline outstanding questions regarding sequencing, dose fractionation, and biomarkers that remain to be addressed for the optimal delivery of this promising treatment approach.

Published
2021
Full Text
View/download PDF

9. Anti-E alloimmunization in a pregnancy with a low antibody titer

Author

K. Nakanishi, Y. Oishi, T. Miyamoto, E. Nakamura, K. Murakami, M. Ono, A. Nozawa, S. Kitamura, and K. Sengoku

Subjects
alloimmunization, anti-e antibody, hemolytic disease of the fetus and newborn, pregnancy, rho(d) immunoglobulin., Gynecology and obstetrics, RG1-991
Abstract

Red blood cell alloimmunization during pregnancy causes hemolytic disease of the fetus and newborn. While alloimmunization in pregnancy is treatable with anti-D antibodies, management with other antibodies has not been studied. A 32-year-old woman had anti-E antibodies detected during pregnancy, but the titer was < 1 : 2. Her newborn was admitted to hospital because direct Coombs tests were positive. Low titers of maternal anti-E antibodies were found in the newborn. We performed phototherapy and administered intravenous immunoglobulin because the newborn showed early jaundice and hyperkalemia, which suggested hemolytic disease. After being discharged at 6 days of age, the baby was readmitted to hospital at 9 days because of recurrent jaundice and underwent phototherapy. The baby was later discharged without recurrence of jaundice. Low anti-E antibody titers in pregnancy can cause alloimmunization, which can be treated successfully. The potential risk of hemolytic disease should be considered in cases with such low titers.

Published
2020
Full Text
View/download PDF

10. Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers

Author

Ikenna, Madueke, Richard J, Lee, and David T, Miyamoto

Subjects
Male, Urologic Neoplasms, Urology, Biomarkers, Tumor, Liquid Biopsy, Humans, Neoplastic Cells, Circulating, Circulating Tumor DNA
Abstract

Liquid biopsies such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have great potential to serve as prognostic and predictive biomarkers in urologic cancers. The possibility of using liquid biopsies for real-time noninvasive and dynamic monitoring of response to therapy has been an active area of investigation. In this brief review, we outline the evidence for the potential clinical utility of CTC and ctDNA analyses in prostate, urothelial, and renal cancers.

Published
2023

11. Long-term stabilization of carrier envelope phases of mid-infrared pulses for the precise detection of phase-sensitive responses to electromagnetic waves

Author

T. Yamakawa, N. Sono, T. Kitao, T. Morimoto, N. Kida, T. Miyamoto, and H. Okamoto

Subjects
Physics, QC1-999
Abstract

We report a high performance mid-infrared pump visible probe measurement system, which can measure phase-sensitive responses to a mid-infrared pulse along the oscillating electromagnetic field. In this system, the pump light is a phase-locked mid-infrared pulse with a temporal width of 100 fs, which is produced via difference frequency generation (DFG) from two idler pulses of two optical parametric amplifiers (OPAs) that are excited by the same Ti:sapphire regenerative amplifier. The probe pulse is a visible pulse with a temporal width of 9 fs and is generated from a custom-built non-collinear OPA. By measuring the electric-field waveforms of mid-infrared pump pulses with electro-optic sampling and evaluating their carrier envelope phase (CEP) and the temporal positions of their envelopes relative to ultrashort visible probe pulses, we are able to perform double feedback corrections that eliminate both the following sources of drift. The CEP drift in mid-infrared pulses originating from fluctuations in the difference of optical-path lengths of the two idler pulses before the DFG is corrected by inserting a wedge plate in one idler path, and the drift in pump–probe delay times due to fluctuations in the difference of the overall optical-path lengths of the pump and probe pulses is corrected with mechanical delay lines. In this double feedback system, the absolute carrier phase of mid-infrared pulses can be fixed within 200 mrad and errors in the measurement of phase-sensitive responses can be reduced to within 1 fs over a few tens of hours.

Published
2020
Full Text
View/download PDF

12. Probing ultrafast spin-relaxation and precession dynamics in a cuprate Mott insulator with seven-femtosecond optical pulses

Author

T. Miyamoto, Y. Matsui, T. Terashige, T. Morimoto, N. Sono, H. Yada, S. Ishihara, Y. Watanabe, S. Adachi, T. Ito, K. Oka, A. Sawa, and H. Okamoto

Subjects
Science
Abstract

Understanding the dynamics of cuprates following photoexcitation can provide insights into the complex coupling mechanisms that underlie their exotic equilibrium behaviour. Here the authors use pump-probe reflection spectroscopy to investigate the nonequilibrium spin dynamics of Mott-insulating Nd2CuO4.

Published
2018
Full Text
View/download PDF

13. Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA

Author

B. P. Abbott, R. Abbott, T. D. Abbott, M. R. Abernathy, F. Acernese, K. Ackley, C. Adams, T. Adams, P. Addesso, R. X. Adhikari, V. B. Adya, C. Affeldt, M. Agathos, K. Agatsuma, N. Aggarwal, O. D. Aguiar, L. Aiello, A. Ain, P. Ajith, T. Akutsu, B. Allen, A. Allocca, P. A. Altin, A. Ananyeva, S. B. Anderson, W. G. Anderson, M. Ando, S. Appert, K. Arai, A. Araya, M. C. Araya, J. S. Areeda, N. Arnaud, K. G. Arun, H. Asada, S. Ascenzi, G. Ashton, Y. Aso, M. Ast, S. M. Aston, P. Astone, S. Atsuta, P. Aufmuth, C. Aulbert, A. Avila-Alvarez, K. Awai, S. Babak, P. Bacon, M. K. M. Bader, L. Baiotti, P. T. Baker, F. Baldaccini, G. Ballardin, S. W. Ballmer, J. C. Barayoga, S. E. Barclay, B. C. Barish, D. Barker, F. Barone, B. Barr, L. Barsotti, M. Barsuglia, D. Barta, J. Bartlett, M. A. Barton, I. Bartos, R. Bassiri, A. Basti, J. C. Batch, C. Baune, V. Bavigadda, M. Bazzan, B. Bécsy, C. Beer, M. Bejger, I. Belahcene, M. Belgin, A. S. Bell, B. K. Berger, G. Bergmann, C. P. L. Berry, D. Bersanetti, A. Bertolini, J. Betzwieser, S. Bhagwat, R. Bhandare, I. A. Bilenko, G. Billingsley, C. R. Billman, J. Birch, R. Birney, O. Birnholtz, S. Biscans, A. Bisht, M. Bitossi, C. Biwer, M. A. Bizouard, J. K. Blackburn, J. Blackman, C. D. Blair, D. G. Blair, R. M. Blair, S. Bloemen, O. Bock, M. Boer, G. Bogaert, A. Bohe, F. Bondu, R. Bonnand, B. A. Boom, R. Bork, V. Boschi, S. Bose, Y. Bouffanais, A. Bozzi, C. Bradaschia, P. R. Brady, V. B. Braginsky, M. Branchesi, J. E. Brau, T. Briant, A. Brillet, M. Brinkmann, V. Brisson, P. Brockill, J. E. Broida, A. F. Brooks, D. A. Brown, D. D. Brown, N. M. Brown, S. Brunett, C. C. Buchanan, A. Buikema, T. Bulik, H. J. Bulten, A. Buonanno, D. Buskulic, C. Buy, R. L. Byer, M. Cabero, L. Cadonati, G. Cagnoli, C. Cahillane, J. Calderón Bustillo, T. A. Callister, E. Calloni, J. B. Camp, K. C. Cannon, H. Cao, J. Cao, C. D. Capano, E. Capocasa, F. Carbognani, S. Caride, J. Casanueva Diaz, C. Casentini, S. Caudill, M. Cavaglià, F. Cavalier, R. Cavalieri, G. Cella, C. B. Cepeda, L. Cerboni Baiardi, G. Cerretani, E. Cesarini, S. J. Chamberlin, M. Chan, S. Chao, P. Charlton, E. Chassande-Mottin, B. D. Cheeseboro, H. Y. Chen, Y. Chen, H.-P. Cheng, A. Chincarini, A. Chiummo, T. Chmiel, H. S. Cho, M. Cho, J. H. Chow, N. Christensen, Q. Chu, A. J. K. Chua, S. Chua, S. Chung, G. Ciani, F. Clara, J. A. Clark, F. Cleva, C. Cocchieri, E. Coccia, P.-F. Cohadon, A. Colla, C. G. Collette, L. Cominsky, M. Constancio, L. Conti, S. J. Cooper, T. R. Corbitt, N. Cornish, A. Corsi, S. Cortese, C. A. Costa, M. W. Coughlin, S. B. Coughlin, J.-P. Coulon, S. T. Countryman, P. Couvares, P. B. Covas, E. E. Cowan, D. M. Coward, M. J. Cowart, D. C. Coyne, R. Coyne, J. D. E. Creighton, T. D. Creighton, J. Cripe, S. G. Crowder, T. J. Cullen, A. Cumming, L. Cunningham, E. Cuoco, T. Dal Canton, S. L. Danilishin, S. D’Antonio, K. Danzmann, A. Dasgupta, C. F. Da Silva Costa, V. Dattilo, I. Dave, M. Davier, G. S. Davies, D. Davis, E. J. Daw, B. Day, R. Day, S. De, D. DeBra, G. Debreczeni, J. Degallaix, M. De Laurentis, S. Deléglise, W. Del Pozzo, T. Denker, T. Dent, V. Dergachev, R. De Rosa, R. T. DeRosa, R. DeSalvo, R. C. Devine, S. Dhurandhar, M. C. Díaz, L. Di Fiore, M. Di Giovanni, T. Di Girolamo, A. Di Lieto, S. Di Pace, I. Di Palma, A. Di Virgilio, Z. Doctor, K. Doi, V. Dolique, F. Donovan, K. L. Dooley, S. Doravari, I. Dorrington, R. Douglas, M. Dovale Álvarez, T. P. Downes, M. Drago, R. W. P. Drever, J. C. Driggers, Z. Du, M. Ducrot, S. E. Dwyer, K. Eda, T. B. Edo, M. C. Edwards, A. Effler, H.-B. Eggenstein, P. Ehrens, J. Eichholz, S. S. Eikenberry, R. A. Eisenstein, R. C. Essick, Z. Etienne, T. Etzel, M. Evans, T. M. Evans, R. Everett, M. Factourovich, V. Fafone, H. Fair, S. Fairhurst, X. Fan, S. Farinon, B. Farr, W. M. Farr, E. J. Fauchon-Jones, M. Favata, M. Fays, H. Fehrmann, M. M. Fejer, A. Fernández Galiana, I. Ferrante, E. C. Ferreira, F. Ferrini, F. Fidecaro, I. Fiori, D. Fiorucci, R. P. Fisher, R. Flaminio, M. Fletcher, H. Fong, S. S. Forsyth, J.-D. Fournier, S. Frasca, F. Frasconi, Z. Frei, A. Freise, R. Frey, V. Frey, E. M. Fries, P. Fritschel, V. V. Frolov, Y. Fujii, M.-K. Fujimoto, P. Fulda, M. Fyffe, H. Gabbard, B. U. Gadre, S. M. Gaebel, J. R. Gair, L. Gammaitoni, S. G. Gaonkar, F. Garufi, G. Gaur, V. Gayathri, N. Gehrels, G. Gemme, E. Genin, A. Gennai, J. George, L. Gergely, V. Germain, S. Ghonge, Abhirup Ghosh, Archisman Ghosh, S. Ghosh, J. A. Giaime, K. D. Giardina, A. Giazotto, K. Gill, A. Glaefke, E. Goetz, R. Goetz, L. Gondan, G. González, J. M. Gonzalez Castro, A. Gopakumar, M. L. Gorodetsky, S. E. Gossan, M. Gosselin, R. Gouaty, A. Grado, C. Graef, M. Granata, A. Grant, S. Gras, C. Gray, G. Greco, A. C. Green, P. Groot, H. Grote, S. Grunewald, G. M. Guidi, X. Guo, A. Gupta, M. K. Gupta, K. E. Gushwa, E. K. Gustafson, R. Gustafson, J. J. Hacker, A. Hagiwara, B. R. Hall, E. D. Hall, G. Hammond, M. Haney, M. M. Hanke, J. Hanks, C. Hanna, M. D. Hannam, J. Hanson, T. Hardwick, J. Harms, G. M. Harry, I. W. Harry, M. J. Hart, M. T. Hartman, C.-J. Haster, K. Haughian, K. Hayama, J. Healy, A. Heidmann, M. C. Heintze, H. Heitmann, P. Hello, G. Hemming, M. Hendry, I. S. Heng, J. Hennig, J. Henry, A. W. Heptonstall, M. Heurs, S. Hild, E. Hirose, D. Hoak, D. Hofman, K. Holt, D. E. Holz, P. Hopkins, J. Hough, E. A. Houston, E. J. Howell, Y. M. Hu, E. A. Huerta, D. Huet, B. Hughey, S. Husa, S. H. Huttner, T. Huynh-Dinh, N. Indik, D. R. Ingram, R. Inta, K. Ioka, H. N. Isa, J.-M. Isac, M. Isi, T. Isogai, Y. Itoh, B. R. Iyer, K. Izumi, T. Jacqmin, K. Jani, P. Jaranowski, S. Jawahar, F. Jiménez-Forteza, W. W. Johnson, D. I. Jones, R. Jones, R. J. G. Jonker, L. Ju, J. Junker, T. Kagawa, T. Kajita, M. Kakizaki, C. V. Kalaghatgi, V. Kalogera, M. Kamiizumi, N. Kanda, S. Kandhasamy, S. Kanemura, M. Kaneyama, G. Kang, J. B. Kanner, S. Karki, K. S. Karvinen, M. Kasprzack, Y. Kataoka, E. Katsavounidis, W. Katzman, S. Kaufer, T. Kaur, K. Kawabe, N. Kawai, S. Kawamura, F. Kéfélian, D. Keitel, D. B. Kelley, R. Kennedy, J. S. Key, F. Y. Khalili, I. Khan, S. Khan, Z. Khan, E. A. Khazanov, N. Kijbunchoo, C. Kim, H. Kim, J. C. Kim, J. Kim, W. Kim, Y.-M. Kim, S. J. Kimbrell, N. Kimura, E. J. King, P. J. King, R. Kirchhoff, J. S. Kissel, B. Klein, L. Kleybolte, S. Klimenko, P. Koch, S. M. Koehlenbeck, Y. Kojima, K. Kokeyama, S. Koley, K. Komori, V. Kondrashov, A. Kontos, M. Korobko, W. Z. Korth, K. Kotake, I. Kowalska, D. B. Kozak, C. Krämer, V. Kringel, B. Krishnan, A. Królak, G. Kuehn, P. Kumar, Rahul Kumar, Rakesh Kumar, L. Kuo, K. Kuroda, A. Kutynia, Y. Kuwahara, B. D. Lackey, M. Landry, R. N. Lang, J. Lange, B. Lantz, R. K. Lanza, A. Lartaux-Vollard, P. D. Lasky, M. Laxen, A. Lazzarini, C. Lazzaro, P. Leaci, S. Leavey, E. O. Lebigot, C. H. Lee, H. K. Lee, H. M. Lee, H. W. Lee, K. Lee, J. Lehmann, A. Lenon, M. Leonardi, J. R. Leong, N. Leroy, N. Letendre, Y. Levin, T. G. F. Li, A. Libson, T. B. Littenberg, J. Liu, N. A. Lockerbie, A. L. Lombardi, L. T. London, J. E. Lord, M. Lorenzini, V. Loriette, M. Lormand, G. Losurdo, J. D. Lough, C. O. Lousto, G. Lovelace, H. Lück, A. P. Lundgren, R. Lynch, Y. Ma, S. Macfoy, B. Machenschalk, M. MacInnis, D. M. Macleod, F. Magaña-Sandoval, E. Majorana, I. Maksimovic, V. Malvezzi, N. Man, V. Mandic, V. Mangano, S. Mano, G. L. Mansell, M. Manske, M. Mantovani, F. Marchesoni, M. Marchio, F. Marion, S. Márka, Z. Márka, A. S. Markosyan, E. Maros, F. Martelli, L. Martellini, I. W. Martin, D. V. Martynov, K. Mason, A. Masserot, T. J. Massinger, M. Masso-Reid, S. Mastrogiovanni, F. Matichard, L. Matone, N. Matsumoto, F. Matsushima, N. Mavalvala, N. Mazumder, R. McCarthy, D. E. McClelland, S. McCormick, C. McGrath, S. C. McGuire, G. McIntyre, J. McIver, D. J. McManus, T. McRae, S. T. McWilliams, D. Meacher, G. D. Meadors, J. Meidam, A. Melatos, G. Mendell, D. Mendoza-Gandara, R. A. Mercer, E. L. Merilh, M. Merzougui, S. Meshkov, C. Messenger, C. Messick, R. Metzdorff, P. M. Meyers, F. Mezzani, H. Miao, C. Michel, Y. Michimura, H. Middleton, E. E. Mikhailov, L. Milano, A. L. Miller, A. Miller, B. B. Miller, J. Miller, M. Millhouse, Y. Minenkov, J. Ming, S. Mirshekari, C. Mishra, V. P. Mitrofanov, G. Mitselmakher, R. Mittleman, O. Miyakawa, A. Miyamoto, T. Miyamoto, S. Miyoki, A. Moggi, M. Mohan, S. R. P. Mohapatra, M. Montani, B. C. Moore, C. J. Moore, D. Moraru, G. Moreno, W. Morii, S. Morisaki, Y. Moriwaki, S. R. Morriss, B. Mours, C. M. Mow-Lowry, G. Mueller, A. W. Muir, Arunava Mukherjee, D. Mukherjee, S. Mukherjee, N. Mukund, A. Mullavey, J. Munch, E. A. M. Muniz, P. G. Murray, A. Mytidis, S. Nagano, K. Nakamura, T. Nakamura, H. Nakano, Masaya Nakano, Masayuki Nakano, K. Nakao, K. Napier, I. Nardecchia, T. Narikawa, L. Naticchioni, G. Nelemans, T. J. N. Nelson, M. Neri, M. Nery, A. Neunzert, J. M. Newport, G. Newton, T. T. Nguyen, W.-T. Ni, A. B. Nielsen, S. Nissanke, A. Nitz, A. Noack, F. Nocera, D. Nolting, M. E. N. Normandin, L. K. Nuttall, J. Oberling, E. Ochsner, E. Oelker, G. H. Ogin, J. J. Oh, S. H. Oh, M. Ohashi, N. Ohishi, M. Ohkawa, F. Ohme, K. Okutomi, M. Oliver, K. Ono, Y. Ono, K. Oohara, P. Oppermann, Richard J. Oram, B. O’Reilly, R. O’Shaughnessy, D. J. Ottaway, H. Overmier, B. J. Owen, A. E. Pace, J. Page, A. Pai, S. A. Pai, J. R. Palamos, O. Palashov, C. Palomba, A. Pal-Singh, H. Pan, C. Pankow, F. Pannarale, B. C. Pant, F. Paoletti, A. Paoli, M. A. Papa, H. R. Paris, W. Parker, D. Pascucci, A. Pasqualetti, R. Passaquieti, D. Passuello, B. Patricelli, B. L. Pearlstone, M. Pedraza, R. Pedurand, L. Pekowsky, A. Pele, F. E. Peña Arellano, S. Penn, C. J. Perez, A. Perreca, L. M. Perri, H. P. Pfeiffer, M. Phelps, O. J. Piccinni, M. Pichot, F. Piergiovanni, V. Pierro, G. Pillant, L. Pinard, I. M. Pinto, M. Pitkin, M. Poe, R. Poggiani, P. Popolizio, A. Post, J. Powell, J. Prasad, J. W. W. Pratt, V. Predoi, T. Prestegard, M. Prijatelj, M. Principe, S. Privitera, G. A. Prodi, L. G. Prokhorov, O. Puncken, M. Punturo, P. Puppo, M. Pürrer, H. Qi, J. Qin, S. Qiu, V. Quetschke, E. A. Quintero, R. Quitzow-James, F. J. Raab, D. S. Rabeling, H. Radkins, P. Raffai, S. Raja, C. Rajan, M. Rakhmanov, P. Rapagnani, V. Raymond, M. Razzano, V. Re, J. Read, T. Regimbau, L. Rei, S. Reid, D. H. Reitze, H. Rew, S. D. Reyes, E. Rhoades, F. Ricci, K. Riles, M. Rizzo, N. A. Robertson, R. Robie, F. Robinet, A. Rocchi, L. Rolland, J. G. Rollins, V. J. Roma, R. Romano, J. H. Romie, D. Rosińska, S. Rowan, A. Rüdiger, P. Ruggi, K. Ryan, S. Sachdev, T. Sadecki, L. Sadeghian, N. Sago, M. Saijo, Y. Saito, K. Sakai, M. Sakellariadou, L. Salconi, M. Saleem, F. Salemi, A. Samajdar, L. Sammut, L. M. Sampson, E. J. Sanchez, V. Sandberg, J. R. Sanders, Y. Sasaki, B. Sassolas, B. S. Sathyaprakash, S. Sato, T. Sato, P. R. Saulson, O. Sauter, R. L. Savage, A. Sawadsky, P. Schale, J. Scheuer, E. Schmidt, J. Schmidt, P. Schmidt, R. Schnabel, R. M. S. Schofield, A. Schönbeck, E. Schreiber, D. Schuette, B. F. Schutz, S. G. Schwalbe, J. Scott, S. M. Scott, T. Sekiguchi, Y. Sekiguchi, D. Sellers, A. S. Sengupta, D. Sentenac, V. Sequino, A. Sergeev, Y. Setyawati, D. A. Shaddock, T. J. Shaffer, M. S. Shahriar, B. Shapiro, P. Shawhan, A. Sheperd, M. Shibata, Y. Shikano, T. Shimoda, A. Shoda, D. H. Shoemaker, D. M. Shoemaker, K. Siellez, X. Siemens, M. Sieniawska, D. Sigg, A. D. Silva, A. Singer, L. P. Singer, A. Singh, R. Singh, A. Singhal, A. M. Sintes, B. J. J. Slagmolen, B. Smith, J. R. Smith, R. J. E. Smith, K. Somiya, E. J. Son, B. Sorazu, F. Sorrentino, T. Souradeep, A. P. Spencer, A. K. Srivastava, A. Staley, M. Steinke, J. Steinlechner, S. Steinlechner, D. Steinmeyer, B. C. Stephens, S. P. Stevenson, R. Stone, K. A. Strain, N. Straniero, G. Stratta, S. E. Strigin, R. Sturani, A. L. Stuver, Y. Sugimoto, T. Z. Summerscales, L. Sun, S. Sunil, P. J. Sutton, T. Suzuki, B. L. Swinkels, M. J. Szczepańczyk, M. Tacca, H. Tagoshi, S. Takada, H. Takahashi, R. Takahashi, A. Takamori, D. Talukder, H. Tanaka, K. Tanaka, T. Tanaka, D. B. Tanner, M. Tápai, A. Taracchini, D. Tatsumi, R. Taylor, S. Telada, T. Theeg, E. G. Thomas, M. Thomas, P. Thomas, K. A. Thorne, E. Thrane, T. Tippens, S. Tiwari, V. Tiwari, K. V. Tokmakov, K. Toland, T. Tomaru, C. Tomlinson, M. Tonelli, Z. Tornasi, C. I. Torrie, D. Töyrä, F. Travasso, G. Traylor, D. Trifirò, J. Trinastic, M. C. Tringali, L. Trozzo, M. Tse, R. Tso, K. Tsubono, T. Tsuzuki, M. Turconi, D. Tuyenbayev, T. Uchiyama, T. Uehara, S. Ueki, K. Ueno, D. Ugolini, C. S. Unnikrishnan, A. L. Urban, T. Ushiba, S. A. Usman, H. Vahlbruch, G. Vajente, G. Valdes, N. van Bakel, M. van Beuzekom, J. F. J. van den Brand, C. Van Den Broeck, D. C. Vander-Hyde, L. van der Schaaf, J. V. van Heijningen, M. H. P. M. van Putten, A. A. van Veggel, M. Vardaro, V. Varma, S. Vass, M. Vasúth, A. Vecchio, G. Vedovato, J. Veitch, P. J. Veitch, K. Venkateswara, G. Venugopalan, D. Verkindt, F. Vetrano, A. Viceré, A. D. Viets, S. Vinciguerra, D. J. Vine, J.-Y. Vinet, S. Vitale, T. Vo, H. Vocca, C. Vorvick, D. V. Voss, W. D. Vousden, S. P. Vyatchanin, A. R. Wade, L. E. Wade, M. Wade, T. Wakamatsu, M. Walker, L. Wallace, S. Walsh, G. Wang, H. Wang, M. Wang, Y. Wang, R. L. Ward, J. Warner, M. Was, J. Watchi, B. Weaver, L.-W. Wei, M. Weinert, A. J. Weinstein, R. Weiss, L. Wen, P. Weßels, T. Westphal, K. Wette, J. T. Whelan, B. F. Whiting, C. Whittle, D. Williams, R. D. Williams, A. R. Williamson, J. L. Willis, B. Willke, M. H. Wimmer, W. Winkler, C. C. Wipf, H. Wittel, G. Woan, J. Woehler, J. Worden, J. L. Wright, D. S. Wu, G. Wu, W. Yam, H. Yamamoto, K. Yamamoto, T. Yamamoto, C. C. Yancey, K. Yano, M. J. Yap, J. Yokoyama, T. Yokozawa, T. H. Yoon, Hang Yu, Haocun Yu, H. Yuzurihara, M. Yvert, A. Zadrożny, L. Zangrando, M. Zanolin, S. Zeidler, J.-P. Zendri, M. Zevin, L. Zhang, M. Zhang, T. Zhang, Y. Zhang, C. Zhao, M. Zhou, Z. Zhou, S. J. Zhu, X. J. Zhu, M. E. Zucker, J. Zweizig, and KAGRA Collaboration, LIGO Scientific Collaboration and Virgo Collaboration

Subjects
Gravitational waves, Gravitational-wave detectors, Electromagnetic counterparts, Data analysis, Atomic physics. Constitution and properties of matter, QC170-197
Abstract

Abstract We present possible observing scenarios for the Advanced LIGO, Advanced Virgo and KAGRA gravitational-wave detectors over the next decade, with the intention of providing information to the astronomy community to facilitate planning for multi-messenger astronomy with gravitational waves. We estimate the sensitivity of the network to transient gravitational-wave signals, and study the capability of the network to determine the sky location of the source. We report our findings for gravitational-wave transients, with particular focus on gravitational-wave signals from the inspiral of binary neutron star systems, which are the most promising targets for multi-messenger astronomy. The ability to localize the sources of the detected signals depends on the geographical distribution of the detectors and their relative sensitivity, and $$90\%$$ 90% credible regions can be as large as thousands of square degrees when only two sensitive detectors are operational. Determining the sky position of a significant fraction of detected signals to areas of 5–$$20~\mathrm {deg}^2$$ 20deg2 requires at least three detectors of sensitivity within a factor of $$\sim 2$$ ∼2 of each other and with a broad frequency bandwidth. When all detectors, including KAGRA and the third LIGO detector in India, reach design sensitivity, a significant fraction of gravitational-wave signals will be localized to a few square degrees by gravitational-wave observations alone.

Published
2018
Full Text
View/download PDF

14. Cochlear implantation in infants below 12 months of age

Author

Richard T. Miyamoto, Bethany Colson, Shirley Henning, and David Pisoni

Subjects
Otorhinolaryngology, RF1-547, Surgery, RD1-811
Abstract

Objectives: To provide safety and efficacy data on infants implanted below 12 months of age. Methods: With the wide application of newborn hearing screening programs, infants with deafness are being identified at birth. When a hearing aid trial fails, cochlear implantation is the only option to restore hearing. Mounting evidence suggests that age at implantation is a strong predictor of language outcomes. Using the minimally invasive surgical technique we have employed for nearly two decades, a limited clinical trial was initiated in the year 2000 because this age limitation fell outside of FDA guidelines. The infants were initially assessed using the preferential listening paradigm to confirm that they could learn associations between speech sounds and objects. Sufficient time was allowed to pass to administer more traditional language measures. Results: No surgical or anesthetic complications occurred in this group of infants. The pattern of listening skill development mirrored that seen in normal hearing infants. Long-term language assessments using the Peabody Picture Vocabulary Test (PPVT) and other measures have demonstrated that many of infants achieved age appropriate language skills. Conclusion: Cochlear implantation in children less than 12 months of age is safe and efficacious as demonstrated by long-term PPVT language data. Keywords: Infants, Cochlear implantation, Treatment outcome

Published
2017
Full Text
View/download PDF

15. Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

Author

Keith H. K. Wong, Shannon N. Tessier, David T. Miyamoto, Kathleen L. Miller, Lauren D. Bookstaver, Thomas R. Carey, Cleo J. Stannard, Vishal Thapar, Eric C. Tai, Kevin D. Vo, Erin S. Emmons, Haley M. Pleskow, Rebecca D. Sandlin, Lecia V. Sequist, David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Shannon L. Stott, and Mehmet Toner

Subjects
Science
Abstract

The current FDA-approved whole blood stabilization method for circulating tumor cell (CTC) isolation suffers from RNA degradation. Here the authors combine hypothermic preservation and antiplatelet strategies to stabilize whole blood up to 72 h without compromising CTC yield and RNA integrity.

Published
2017
Full Text
View/download PDF

18. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination

Author

Yu Zheng, David T. Miyamoto, Ben S. Wittner, James P. Sullivan, Nicola Aceto, Nicole Vincent Jordan, Min Yu, Nezihi Murat Karabacak, Valentine Comaills, Robert Morris, Rushil Desai, Niyati Desai, Erin Emmons, John D. Milner, Richard J. Lee, Chin-Lee Wu, Lecia V. Sequist, Wilhelm Haas, David T. Ting, Mehmet Toner, Sridhar Ramaswamy, Shyamala Maheswaran, and Daniel A. Haber

Subjects
Science
Abstract

Circulating tumour cells contribute to metastatic spread. Here the authors find that beta-chain of haemoglobin is overexpressed in those cells and protects them from oxidative stress, prolonging their survival in circulation and thereby increasing the likelihood of metastasis formation.

Published
2017
Full Text
View/download PDF

20. Supplementary Tables 1-2 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer

Author

Daniel A. Haber, Shyamala Maheswaran, Mehmet Toner, Sridhar Ramaswamy, Matthew R. Smith, Lecia V. Sequist, Chin-Lee Wu, Neil H. Bander, Julie Trautwein, Brian W. Brannigan, Jenna B. Lord, Malgorzata E. Smas, Matthew Ulman, Ben S. Wittner, David T. Ting, Shannon L. Stott, Richard J. Lee, and David T. Miyamoto

Abstract

PDF file - 110K, Supplemental Tables. (S1) Clinical characteristics and CTC data for metastatic prostate cancer patients treated with hormonal therapy. (S2) Time course data for metastatic prostate cancer patients treated with hormonal therapy and analyzed for AR signaling in CTCs.

Published
2023

21. Tables S1, S2, S3, S4, S5 from An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer

Author

Daniel A. Haber, Shyamala Maheswaran, Mehmet Toner, Anita Giobbie-Hurder, David T. Ting, Shannon L. Stott, Chin-Lee Wu, Ravi Kapur, Lecia V. Sequist, Matthew R. Smith, Jason A. Efstathiou, Francis J. McGovern, Douglas M. Dahl, Xin Hong, Tanya Todorova Kwan, Sarah Javaid, Erin Silva, Katherine Broderick, Uyen Ho, Erin Emmons, John D. Milner, Tianqi Chen, Yu Zheng, Joseph A. LiCausi, Mark Kalinich, Richard J. Lee, and David T. Miyamoto

Abstract

Supplementary Table S1. Genes tested for Prostate CTC digital PCR Assay; Supplementary Table S2. Clinical information for prostate cancer patients and healthy donor subjects; Supplementary Table S3. Clinical information for patients enrolled on prospective trial of first-line abiraterone for mCRPC; Supplementary Table S4. Clinical information for patients with localized prostate cancer in radical prostatectomy study; Supplementary Table S5. Droplet digital PCR primers used in this study.

Published
2023

22. Supplementary Tables from A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer

Author

Shyamala Maheswaran, Daniel A. Haber, Mehmet Toner, David T. Miyamoto, Ravi Kapur, Lecia V. Sequist, Ben S. Wittner, Erin J. Silva, Uyen Ho, Joseph A. LiCausi, Xin Hong, Tilak Sundaresan, Taronish Dubash, Mark Kalinich, Anita Giobbie-Hurder, Laura M. Spring, Aditya Bardia, and Tanya T. Kwan

Abstract

All supplementary tables

Published
2023

23. Figures S1, S2, S3, S4, S5, S6 from An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer

Author

Daniel A. Haber, Shyamala Maheswaran, Mehmet Toner, Anita Giobbie-Hurder, David T. Ting, Shannon L. Stott, Chin-Lee Wu, Ravi Kapur, Lecia V. Sequist, Matthew R. Smith, Jason A. Efstathiou, Francis J. McGovern, Douglas M. Dahl, Xin Hong, Tanya Todorova Kwan, Sarah Javaid, Erin Silva, Katherine Broderick, Uyen Ho, Erin Emmons, John D. Milner, Tianqi Chen, Yu Zheng, Joseph A. LiCausi, Mark Kalinich, Richard J. Lee, and David T. Miyamoto

Abstract

Supplementary Figure S1. (A) Schematic of d-CTC assay. Whole blood is processed using the CTC-iChip, resulting in a bulk product highly enriched for intact CTCs (labeled green) but also contains WBCs (labeled red) and RBCs (unlabeled); Supplementary Figure S2. Graphs showing droplet digital PCR signal for each gene in 12 metastatic prostate cancer patients compared to 34 healthy male control subjects; Supplementary Figure S3. (A, B) Graphs of relationships between Prostate CTCM Score and serum PSA, and CTC droplet digital PCR KLK3 signal and serum PSA at the pre-treatment time point; Supplementary Figure S4. (A) Kaplan-Meier curves for radiographic progression-free survival (R-PFS) by CTC HOXB13 status at pretreatment; Supplementary Figure S5. (A) Heatmap of droplet digital PCR CTC signal after whole transcriptome amplification for blood samples from healthy donor controls arranged by sex and age, and from patients with clinically localized prostate cancer, arranged by D'Amico Risk Group; Supplementary Figure S6. (A) Box plots showing pre-operative leave-one-out cross validated (LOOCV) CTCL Score in clinically localized prostate cancer patients according to microscopic SVI or pelvic LN involvement identified at the time of radical prostatectomy

Published
2023

24. Supplementary figures from A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer

Author

Shyamala Maheswaran, Daniel A. Haber, Mehmet Toner, David T. Miyamoto, Ravi Kapur, Lecia V. Sequist, Ben S. Wittner, Erin J. Silva, Uyen Ho, Joseph A. LiCausi, Xin Hong, Tilak Sundaresan, Taronish Dubash, Mark Kalinich, Anita Giobbie-Hurder, Laura M. Spring, Aditya Bardia, and Tanya T. Kwan

Abstract

All supplementary figures

Published
2023

25. Supplementary methods from A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer

Author

Shyamala Maheswaran, Daniel A. Haber, Mehmet Toner, David T. Miyamoto, Ravi Kapur, Lecia V. Sequist, Ben S. Wittner, Erin J. Silva, Uyen Ho, Joseph A. LiCausi, Xin Hong, Tilak Sundaresan, Taronish Dubash, Mark Kalinich, Anita Giobbie-Hurder, Laura M. Spring, Aditya Bardia, and Tanya T. Kwan

Abstract

Methods describing microfluidic CTC enrichment, RNA extraction, amplification and detection, single cell and bulk RNA sequencing

Published
2023

26. Supplementary Methods from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer

Author

Daniel A. Haber, Shyamala Maheswaran, Mehmet Toner, Sridhar Ramaswamy, Matthew R. Smith, Lecia V. Sequist, Chin-Lee Wu, Neil H. Bander, Julie Trautwein, Brian W. Brannigan, Jenna B. Lord, Malgorzata E. Smas, Matthew Ulman, Ben S. Wittner, David T. Ting, Shannon L. Stott, Richard J. Lee, and David T. Miyamoto

Abstract

PDF file - 49K, Supplemental Methods for (a) single molecule sequencing and AR transcriptional signature, (b) HB CTC-chip fabrication, (c) HB CTC-chip blood processing, and (d) automated fluorescence microscopy.

Published
2023

27. Supplementary Data from Molecular Characterization of Neuroendocrine-like Bladder Cancer

Author

Peter C. Black, Yair Lotan, Jason A. Efstathiou, Omar Y. Mian, Siamak Daneshmand, Roland Seiler, Badrinath R. Konety, Seong Ra, Ladan Fazli, Paari Murugan, Kent W. Mouw, Petros Grivas, Shilpa Gupta, Bas W.G. van Rhijn, Chin-Lee Wu, Michiel S. Van der Heijden, Joost L. Boormans, James Douglas, Marc A. Dall’Era, Jonathan Wright, Elai Davicioni, Mohammed Alshalalfa, David T. Miyamoto, Htoo Zarni Oo, Yang Liu, Trinity J. Bivalacqua, Ewan A. Gibb, and José Batista da Costa

Abstract

Supplemental Tables

Published
2023

28. Supplementary Figures from Molecular Characterization of Neuroendocrine-like Bladder Cancer

Author

Peter C. Black, Yair Lotan, Jason A. Efstathiou, Omar Y. Mian, Siamak Daneshmand, Roland Seiler, Badrinath R. Konety, Seong Ra, Ladan Fazli, Paari Murugan, Kent W. Mouw, Petros Grivas, Shilpa Gupta, Bas W.G. van Rhijn, Chin-Lee Wu, Michiel S. Van der Heijden, Joost L. Boormans, James Douglas, Marc A. Dall’Era, Jonathan Wright, Elai Davicioni, Mohammed Alshalalfa, David T. Miyamoto, Htoo Zarni Oo, Yang Liu, Trinity J. Bivalacqua, Ewan A. Gibb, and José Batista da Costa

Abstract

Supplemental figures and box plots

Published
2023

29. Data from Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer

Author

David T. Miyamoto, Chin-Lee Wu, David T. Ting, Miguel N. Rivera, Erika Meneely, Kara Olivier, Rong Hu, Vikram Deshpande, Kshitij S. Arora, Richard J. Lee, and Philip J. Saylor

Abstract

Purpose: The androgen receptor (AR) mRNA splice variant AR-V7 has emerged as a predictive biomarker for response to AR-targeted therapies. There are currently no commercially available assays to detect AR splice variants. The branched chain RNA in situ hybridization (ISH) platform enables the highly sensitive detection of RNA transcripts in formalin-fixed, paraffin-embedded (FFPE) tissues.Experimental design: We designed a branched chain RNA ISH probe to target the unique cryptic exon CE3 of AR-V7 using multiple tiling probes. This automated ISH assay was applied to tumor tissue from two distinct clinical cohorts that we hypothesized would differ in AR-V7 status.Results: We detected AR-V7 in all tumor samples from men with metastatic castration-resistant prostate cancer with tissue obtained after disease progression despite at least one subsequent line of hormonal therapy (abiraterone, enzalutamide, or bicalutamide; n = 12). We detected AR-V7 in just one tumor from men who had undergone prostatectomy for localized adenocarcinoma (n = 30; Gleason 4 + 5 = 9 in the AR-V7–positive sample). Given the apparent distinction between the above groups by AR-V7 signal, we analyzed pretreatment AR-V7 status as a predictive and prognostic biomarker in men with treatment-naïve metastatic disease. Patients with metastases but without detectable AR-V7 RNA at baseline had significantly longer overall survival (log-rank P = 0.044) and a trend toward superior progression-free survival (log-rank P = 0.055).Conclusions: Within an institutional cohort, the RNA ISH assay identified AR-V7 within FFPE tissue and may have prognostic value in metastatic castration-sensitive prostate cancer. These preliminary findings warrant further study in larger cohorts. Clin Cancer Res; 23(2); 363–9. ©2016 AACR.

Published
2023

30. Data from Molecular Characterization of Neuroendocrine-like Bladder Cancer

Author

Peter C. Black, Yair Lotan, Jason A. Efstathiou, Omar Y. Mian, Siamak Daneshmand, Roland Seiler, Badrinath R. Konety, Seong Ra, Ladan Fazli, Paari Murugan, Kent W. Mouw, Petros Grivas, Shilpa Gupta, Bas W.G. van Rhijn, Chin-Lee Wu, Michiel S. Van der Heijden, Joost L. Boormans, James Douglas, Marc A. Dall’Era, Jonathan Wright, Elai Davicioni, Mohammed Alshalalfa, David T. Miyamoto, Htoo Zarni Oo, Yang Liu, Trinity J. Bivalacqua, Ewan A. Gibb, and José Batista da Costa

Abstract

Purpose:Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant. Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer (MIBC) have transcriptomic patterns consistent with NE bladder cancer in the absence of NE histology. The clinical implications of this NE-like subtype have not been explored in depth.Experimental Design:Transcriptome-wide expression profiles were generated for MIBC collected from 7 institutions and clinical-use of Decipher Bladder. Using unsupervised clustering, we generated a clustering solution on a prospective training cohort (PTC; n = 175), developed single-sample classifiers to predict NE tumors, and evaluated the resultant models on a testing radical cystectomy (RC) cohort (n = 225). A random forest model was finalized and applied to 5 validation cohorts (n = 1302). Uni- and multivariable survival analyses were used to characterize clinical outcomes.Results:In the training cohort (PTC), hierarchical clustering using an 84-gene panel showed a cluster of 8 patients (4.6%) with highly heterogeneous expression of NE markers in the absence of basal or luminal marker expression. NE-like tumors were identified in 1% to 6.6% of cases in validation cohorts. Patients with NE-like tumors had significantly worse 1-year progression-free survival (65% NE-like vs. 82% overall; P = 0.046) and, after adjusting for clinical and pathologic factors, had a 6.4-fold increased risk of all-cause mortality (P = 0.001). IHC confirmed the neuronal character of these tumors.Conclusions:A single-patient classifier was developed that identifies patients with histologic urothelial cancer harboring a NE transcriptomic profile. These tumors represent a high-risk subgroup of MIBC, which may require different treatment.

Published
2023

33. Experimental verification of charge soliton excitations in the ionic Mott-Peierls ferroelectric TTF-CA

Author

R. Takehara, H. Adachi, K. Sunami, K. Miyagawa, T. Miyamoto, H. Okamoto, S. Horiuchi, and K. Kanoda

Subjects
Condensed Matter - Strongly Correlated Electrons, Nonlinear Sciences::Exactly Solvable and Integrable Systems, Strongly Correlated Electrons (cond-mat.str-el), FOS: Physical sciences, Condensed Matter::Strongly Correlated Electrons, Nonlinear Sciences::Pattern Formation and Solitons
Abstract

Strong coupling of charge, spin, and lattice in solids brings about emergent elementary excitations with their intertwining and, in one dimension, solitons are known as such. The charge-transferred organic ferroelectric, TTF-CA, has been argued to host charge solitons; however, the existence of the charge solitons remains unverified. Here, we demonstrate that the charge-transport gap in the ionic Mott-Peierls insulating phase of TTF-CA is an order of magnitude smaller than expected from quasiparticle excitations, however, being entirely consistent with the charge soliton excitations. We further suggest that charge and spin solitons move with similar diffusion coefficients in accordance with their coexistence. These results provide a basis for the thermal excitations of the emergent solitons., 6 pages, 3 figures

Published
2023

39. Activity-dependent glassy cell mechanics I : Mechanical properties measured with active microrheology

Author

H. Ebata, K. Umeda, K. Nishizawa, W. Nagao, S. Inokuchi, Y. Sugino, T. Miyamoto, and D. Mizuno

Abstract

Active microrheology was conducted in living cells by applying an optical-trapping force to vigorously-fluctuating tracer beads with feedback-tracking technology. The complex shear viscoelastic modulusG(ω) =G′(ω) –iG″(ω) was measured in HeLa cells in an epithelial-like confluent monolayer. We found thatG(ω) ∝ (−iω)1/2over a wide range of frequencies (1 Hz <ω/2πG(ω) in living cells. On the other hand,G(ω) was found to be dependent on cell metabolism; ATP-depleted cells showed an increased elastic modulusG′(ω) at low frequencies, giving rise to a constant plateau such thatG(ω) =G0+A(−iω)1/2. Both the plateau and the additional frequency dependency ∝ (−iω)1/2of ATP-depleted cells are consistent with a rheological response typical of colloidal jamming. On the other hand, the plateauG0disappeared in ordinary metabolically active cells, implying that living cells fluidize their internal states such that they approach the critical jamming point.Statement of SignificanceIntracellular mechanical properties were measured using optical-trap-based microrheology. Despite expectations to the contrary, shear viscoelasticity was hardly affected by reorganization of cytoskeletal structures during cell-cycle progression (G1 to S and G2 phases), nor by artificial disruption of the actin cytoskeleton induced by chemical inhibitors. Rather, the mechanics of cell interiors is governed by the glassy cytoplasm. Cells depleted of ATP solidified, whereas living cells that maintained metabolic activities were more fluid-like. Instead of a completely fluid response, however, we observed a characteristic power-law viscoelasticityG(ω) ∝ (−iω)1/2over the whole range of frequencies measured. Based on our current understanding of jamming rheology, we discuss how cells fluidize their internal state in a way that pushes the system towards the critical jamming transition.

Published
2022

42. Characteristics of Fault Rocks Within the Aftershock Cloud of the 2014 Orkney Earthquake (M5.5) Beneath the Moab Khotsong Gold Mine, South Africa

Author

T. Miyamoto, T. Hirono, Y. Yokoyama, S. Kaneki, Y. Yamamoto, T. Ishikawa, A. Tsuchiyama, I. Katayama, Y. Yabe, M. Ziegler, R. J. Durrheim, and H. Ogasawara

Subjects
earthquake, fault drilling, lamprophyre, Geophysics, General Earth and Planetary Sciences
Abstract

Cores recovered during the International Continental Scientific Drilling Program project "Drilling into Seismogenic zones of M2.0 to M5.5 earthquakes in deep South African Gold Mines" include fault breccia from within the aftershock cloud of the 2014 Orkney earthquake (M5.5). The breccia and surrounding intrusive rocks, probably lamprophyres rich in talc, biotite, calcite, and amphibole, had high magnetic susceptibilities owing to the presence of magnetite. All of these characteristics can be attributed to fluid-related alteration. Both the breccia and the lamprophyres had low friction coefficients and showed evidence of velocity strengthening, which is inconsistent with the occurrence of earthquakes. Variable amounts of talc, biotite, calcite, and amphibole within the lamprophyres might have produced complex frictional properties and spatial heterogeneity of fault stability. The altered lamprophyres may be the host rocks of the 2014 Orkney earthquake, but frictional complexity may have governed the magnitudes of the main- and aftershocks and their distributions., Geophysical Research Letters, 49 (14), ISSN:0094-8276, ISSN:1944-8007

Published
2022

43. Object Classification and Segmentation Based on Deep Learning Using Underwater Mapping Data

Author

H. Okawa, S. Omoto, S. Yagi, T. Miyamoto, and K. Kashiyama

Abstract

This paper presents a fast and accurate classification method for underwater objects using underwater mapping data obtained by a small Autonomous Underwater Vehicle (AUV) and autonomous surface vehicle (ASV). For the mapping data, in addition to underwater acoustic reflection intensity images, water depth data, point cloud data and backscattering reflection intensity data are employed. We propose the automatic classification and semantic segmentation method on deep learning using a convolutional neural network (CNN) and PointNet++. In order to verify the effectiveness of the present method, we applied it to the measured several underwater mapping data.

Published
2022

44. Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells

Author

David T. Ting, Ben S. Wittner, Matteo Ligorio, Nicole Vincent Jordan, Ajay M. Shah, David T. Miyamoto, Nicola Aceto, Francesca Bersani, Brian W. Brannigan, Kristina Xega, Jordan C. Ciciliano, Huili Zhu, Olivia C. MacKenzie, Julie Trautwein, Kshitij S. Arora, Mohammad Shahid, Haley L. Ellis, Na Qu, Nabeel Bardeesy, Miguel N. Rivera, Vikram Deshpande, Cristina R. Ferrone, Ravi Kapur, Sridhar Ramaswamy, Toshi Shioda, Mehmet Toner, Shyamala Maheswaran, and Daniel A. Haber

Subjects
Biology (General), QH301-705.5
Abstract

Circulating tumor cells (CTCs) are shed from primary tumors into the bloodstream, mediating the hematogenous spread of cancer to distant organs. To define their composition, we compared genome-wide expression profiles of CTCs with matched primary tumors in a mouse model of pancreatic cancer, isolating individual CTCs using epitope-independent microfluidic capture, followed by single-cell RNA sequencing. CTCs clustered separately from primary tumors and tumor-derived cell lines, showing low-proliferative signatures, enrichment for the stem-cell-associated gene Aldh1a2, biphenotypic expression of epithelial and mesenchymal markers, and expression of Igfbp5, a gene transcript enriched at the epithelial-stromal interface. Mouse as well as human pancreatic CTCs exhibit a very high expression of stromal-derived extracellular matrix (ECM) proteins, including SPARC, whose knockdown in cancer cells suppresses cell migration and invasiveness. The aberrant expression by CTCs of stromal ECM genes points to their contribution of microenvironmental signals for the spread of cancer to distant organs.

Published
2014
Full Text
View/download PDF

45. Bladder preservation: Translating discovery for clinical impact in urothelial cancer

Author

Kent W. Mouw, Philip Abbosh, David T. Miyamoto, and Catharine M L West

Subjects
Oncology, medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, urologic and male genital diseases, Article, Bladder preservation, Cystectomy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Urothelial cancer, Effective treatment, Carcinoma, Transitional Cell, Bladder cancer, business.industry, medicine.disease, Molecular biomarkers, female genital diseases and pregnancy complications, Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Identification (biology), business, Organ Sparing Treatments
Abstract

Muscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer.

Published
2021

48. Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition

Author

Nezihi Murat Karabacak, Yu Zheng, Taronish D. Dubash, Risa Burr, Douglas S. Micalizzi, Ben S. Wittner, Maoxuan Lin, Devon F. Wiley, Valentine Comaills, Erin Emmons, Kira L. Niederhoffer, Uyen Ho, Jacob Ukleja, Dante Che, Hannah Stowe, Linda T. Nieman, Wilhelm Haas, Shannon L. Stott, Michael S. Lawrence, David T. Ting, David T. Miyamoto, Daniel A. Haber, Mehmet Toner, and Shyamala Maheswaran

Subjects
Male, Proteomics, Cancer Research, TOR Serine-Threonine Kinases, Prostatic Neoplasms, Epithelial Cell Adhesion Molecule, Article, Phosphatidylinositol 3-Kinases, Oncology, Cell Line, Tumor, Tumor Microenvironment, Animals, Humans, Protein Kinase Inhibitors
Abstract

Cancer therapy often results in heterogeneous responses in different metastatic lesions in the same patient. Inter- and intratumor heterogeneity in signaling within various tumor compartments and its impact on therapy are not well characterized due to the limited sensitivity of single-cell proteomic approaches. To overcome this barrier, we applied single-cell mass cytometry with a customized 26-antibody panel to PTEN-deleted orthotopic prostate cancer xenograft models to measure the evolution of kinase activities in different tumor compartments during metastasis or drug treatment. Compared with primary tumors and circulating tumor cells (CTC), bone metastases, but not lung and liver metastases, exhibited elevated PI3K/mTOR signaling and overexpressed receptor tyrosine kinases (RTK) including c-MET protein. Suppression of c-MET impaired tumor growth in the bone. Intratumoral heterogeneity within tumor compartments also arose from highly proliferative EpCAM-high epithelial cells with increased PI3K and mTOR kinase activities coexisting with poorly proliferating EpCAM-low mesenchymal populations with reduced kinase activities; these findings were recapitulated in epithelial and mesenchymal CTC populations in patients with metastatic prostate and breast cancer. Increased kinase activity in EpCAM-high cells rendered them more sensitive to PI3K/mTOR inhibition, and drug-resistant EpCAM-low populations with reduced kinase activity emerged over time. Taken together, single-cell proteomics indicate that microenvironment- and cell state–dependent activation of kinase networks create heterogeneity and differential drug sensitivity among and within tumor populations across different sites, defining a new paradigm of drug responses to kinase inhibitors. Significance: Single-cell mass cytometry analyses provide insights into the differences in kinase activities across tumor compartments and cell states, which contribute to heterogeneous responses to targeted therapies.

Published
2022

50. Response of Self-Centering Mass Plywood Panel Shear Walls

Author

Ian Morrell, Arijit Sinha, Rajendra Soti, and Byrne T. Miyamoto

Subjects
Materials science, Shear wall, General Materials Science, Forestry, Slip (materials science), Composite material, Dissipation, Residual, Damper
Abstract

The rocking behavior of self-centering mass plywood panel (MPP) walls was investigated with and without the use of supplementary energy dissipation systems. Two energy dissipation systems were tested. The first system used a kinematically expanding hysteretic damper (KE-HD), whereas the second system used slip friction connections (SFCs). The reviewed energy dissipating systems were used in a self-centering system comprising one unbonded posttensioned (PT) hold-down rod on each side of the MPP walls. The cyclic performance of the PT and the hybrid MPP specimens was investigated through a series of full-scale quasi-static cyclic tests. The test results demonstrated the viability of the investigated energy dissipaters in self-centering MPP rocking systems. Results further indicate that hybrid specimens with SFC dissipate more energy and provide higher strength than those with KE-HDs, however, with higher residual drift.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results